Jump Financial, LLC Novavax Inc Transaction History

Jump Financial, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 21, 2024	BUY	$6.81 - $9.74 $417,275 - $596,808	61,274 Added 25.4%	302,473 $2.19 Million
Q3 2023 Nov 07, 2023	BUY	$6.81 - $9.74 $417,275 - $596,808	61,274 Added 25.4%	302,473 $2.19 Million
Q2 2023 Oct 21, 2024	SELL	$6.67 - $9.52 $1.13 Million - $1.62 Million	-169,715 Reduced 41.3%	241,199 $1.79 Million
Q2 2023 Aug 07, 2023	SELL	$6.67 - $9.52 $1.13 Million - $1.62 Million	-169,715 Reduced 41.3%	241,199 $1.79 Million
Q1 2023 Oct 21, 2024	BUY	$5.76 - $12.48 $2.37 Million - $5.13 Million	410,914 New	410,914 $2.85 Million
Q1 2023 May 03, 2023	BUY	$5.76 - $12.48 $2.37 Million - $5.13 Million	410,914 New	410,914 $2.85 Million
Q2 2022 Aug 09, 2022	BUY	$36.28 - $75.29 $2.73 Million - $5.67 Million	75,356 New	75,356 $3.88 Million
Q1 2022 May 12, 2022	SELL	$69.73 - $142.9 $118,541 - $242,930	-1,700 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$134.56 - $217.97 $228,752 - $370,549	1,700 New	1,700 $243,000
Q4 2020 Feb 12, 2021	SELL	$78.74 - $139.5 $816,691 - $1.45 Million	-10,372 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$79.44 - $178.51 $823,951 - $1.85 Million	10,372 New	10,372 $1.12 Million

284

84.8M

5.43M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $731M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.